Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The study of prognostic factors in patients with prostate cancer (Pca) may be of value in understanding the natural history of the disease and may also assist in planning and analyzing the results of clinical trials. Moreover some information through this study would be beneficial to assessing the prognosis and decision of better therapy form of individual patients. The significance of items studied was evaluated from the two view points, survival rate and Pca death rate. Stage, pathological differentiation and acid phosphatase were significantly related to them, in the category grade depending manner. Past history and complication, and age were also significantly related to them but higher category grade as a survival factor showed lower Pca death rates. ESR, gait disturbance and hematuria were related to only survival rate. Any significant relationship was not observed in serum testosterone, voiding disturbance and cancer-pain. Prognostic factors should be clinically used through the well understanding of each characteristics. This paper also showed that statistical significance not always provide a wide difference between categories compared.
 ...
PMID:[Prognostic factor for prostate cancer. Gunma Urological Oncology Study Group]. 223 14

In this open pilot study a combination of hydroxychloroquine, prednisolone and alternating months of treatment with sulphasalazine or oral weekly pulse methotrexate has been investigated in 16 patients with rheumatoid arthritis (RA) refractory to a total of 67 disease suppressive medications. Results at 3 months indicated significant improvements in visual analogue score for pain, joint count, Ritchie index, scale of disability related to activities of daily living, ESR, rheumatoid factor and C-reactive protein. This degree of improvement, however, was not maintained 6 and 12 months after commencement of treatment. Pain score, Ritchie index and ESR were the only parameters demonstrating significant improvement at 12 months. Therapy was terminated in eight patients, half due to lack of efficacy and half because of side effects.
 ...
PMID:The cycling of combination antirheumatic drug therapy in rheumatoid arthritis. 186 32

A 6-month double-blind study of OM-8980 and auranofin in 145 patients with rheumatoid arthritis was followed by an open observation period of 6 months for which 100 OM-8980-treated patients could be assessed. At the end of this second phase, the Ritchie index, number of swollen joints, pain scale, morning stiffness, grip strength and ESR had all improved further with respect to the significant improvements already recorded under OM-8980 and auranofin in the double-blind phase. The statistical analysis of the Ritchie index, pain scale and ESR showed significant changes in these 3 parameters during both the 6-month follow-up phase and the entire 12-month period. As regards the tolerance, 2 patients reported gastrointestinal disorders during the follow-up. The investigators' final assessment of efficacy indicated an improvement in 76% of the patients during the follow-up phase and in 95% during the entire 12-month period.
 ...
PMID:Follow-up with OM-8980 after a double-blind study of OM-8980 and auranofin in rheumatoid arthritis. 226 35

During holidays in Suriname a six year old boy fell ill with high fever, general malaise, pain in the extremities and abdomen and vomiting. Because of a tentative diagnosis of acute rheumatism or bacterial enteritis amoxicillin and salicylates were started. After his return to the Netherlands an increased ESR and impaired renal and hepatic functions were found. The history revealed contact with sewage water. Further analysis established the diagnosis of Leptospirosis. This comparatively rare clinical entity, seldom mentioned in paediatric literature, is discussed.
 ...
PMID:[A patient with fever and pain in the extremities]. 237 42

The clinical, pathological, and epidemiological relationships between fasting plasma glucose (FPG) concentrations and the sites of lesion in osteoarthritis (OA) were evaluated in 1026 patients. The mean FPG (99 +/- 22.2 mg/dL) was significantly higher in OA (p less than 0.01) than in the normal controls (88 +/- 19.9 mg/dL). In addition, the mean FPG (97.9 +/- 23 mg/dL) was significantly higher in female patients with OA (p less than 0.01) than in an osteoporotic sex-matched control group (92.8 +/- 24.5). FPG concentrations did not vary significantly according to the sites of the OA lesions. Fifty-six (5.5%) OA patients had long-term diabetes mellitus (FPG greater than 140 mg/dl). Few significant differences in the pathological and clinical findings were seen between normoglycemic and hyperglycemic OA patients, only the ESR (p less than 0.01) and pain at rest (p less than 0.02) being higher in the second group. These epidemiological data support the observation that hyperglycemia, which acts on matrix macromolecules, may be related to the development of bone degenerative disease.
 ...
PMID:Plasma glucose concentration in symptomatic osteoarthritis: a clinical and epidemiological survey. 237 41

One hundred and thirty-two patients with renal cell carcinoma, treated by the TEKK Group, during the period from 1962 to 1983 were clinically reviewed. The patients ranged in age from 13 to 77 years with a mean age of 57.3 years, and were 89 men and 44 women, with a sex ratio of 2.07 to 1. The most common symptom was hematuria (55.4%), followed by palpable mass (19.2%), pain (13.8%) and fever (6.9%). The distant metastasis was observed in 26 patients (19.7%), mostly in the lung (54%) and the bone (19%). Overall estimated survival rates at 1,3 and 5 year were 83.0%, 58.2% and 56.9% respectively. The prognosis of the patients with renal cell carcinoma was dependent upon affected site, age, ESR, CRP, alpha 2-globulin and distant metastasis.
 ...
PMID:[A clinical study on renal cell carcinoma]. 241 20

The efficacy and safety of the new non-steroidal antiinflammatory drug flunoxaprofen were compared with those of naproxen in a cross over clinical study in patients with classical or definite rheumatoid arthritis (RA). Twenty female out-patients in the active phase of the disease were randomly assigned to one of the two groups studied; one group (A: 10 patients, mean age 51 years) received flunoxaprofen 400 mg/day p.o. for 30 days, followed by a 7-day wash-out period before starting the second treatment, with naproxen 500 mg/day p.o. for 30 days. Another group (B: 10 patients, mean age 58 years) received naproxen before flunoxaprofen and followed the same schedule of group A. The results showed that flunoxaprofen and naproxen have essentially equivalent therapeutical effects in controlling painful and functional symptoms of RA: both treatments resulted in a significant relief of spontaneous diurnal and nocturnal pain, pain on active and passive motion, morning stiffness, and in a significant improvement of grip strength and Richtie's index. None of the two drugs modified biochemical parameters of inflammation (ESR, CPR) or the laboratory variables measured to assess the tolerability of flunoxaprofen (hepatorenal function tests; haematological parameters). Flunoxaprofen was found to be very well tolerated: this feature together with the good therapeutic efficacy makes flunoxaprofen a very safe and useful tool in the management of severe chronic disease such as RA.
 ...
PMID:[Efficacy and tolerability of flunoxaprofen in the treatment of rheumatoid arthritis. A cross-over clinical study using naproxen]. 253 24

Between November 1984 and July 1988 a total of 8044 randomly selected German residents of the city of Hannover/FRG, aged 25 to 74, have been screened for rheumatic complaints by means of a postal questionnaire. An average 87% of the probands contacted returned completed questionnaires. Respondents with a "positive" questionnaire, i.e. suggestive of the existence of an inflammatory joint disease were invited for a rheumatological examination at the Hannover Medical School. 72% participated. 45 of a total of 1291 participants were identified as suffering from active or inactive, mostly rheumatoid arthritis. This yields a minimum prevalence of 0.56% (+/- 0.19%). The true prevalence is estimated to be 0.91% (99%-confidence interval 0.64-1.18). In 1985 and 1986 103 German RA sufferers aged 25 to 74, all citizens of Hannover, were referred to our outpatient rheumatology clinic for a first consultation. A comparison between the two groups revealed a higher disease activity in terms of "objective" criteria (joint swellings, ESR, rheumatoid factor) in the group of the referred patients as opposed to RA suffers from the community. Both groups were comparable in respect to "subjective" symptoms (morning stiffness, joint pain, pain intensity), functional capacity and degree of erosive joint lesions. The rheumatological outpatient clinic at the Hannover Medical School, providing the only specialized service in the region, actually covers less than 20% of all RA sufferers within the municipal area of Hannover and less than 50% of those with a "classical" RA according to the ARA-criteria.
 ...
PMID:Activity and severity of rheumatoid arthritis in Hannover/FRG and in one regional referral center. 259 38

Polymyalgia rheumatica can be characterised by pain and stiffness in the shoulder and pelvic girdles, with a raised ESR and a dramatic response to corticosteroid therapy. Case reports and clinical symptoms of six patients with polymyalgia rheumatica are reported by the authors. All of the patients were female with mean age 54.3 years. 11.8 months were registered between the initial symptoms of the disease and the establishment of the diagnosis. This relatively long period of time can be caused by the poor recognition of the disease, besides the difficulties of the diagnosis.
 ...
PMID:[Incidence of polymyalgia rheumatica at a department of internal medicine]. 266 61

Cytokines such as Interleukin-1 (IL-1) are important modulators of the cell-mediated immune response and play a paramount role in inflammatory autoimmune disease. We report on preliminary clinical experiences with a new, tricyclic substance [( 10-Methoxy-4H-benzo[4,5]cyclo-hepta-[1,2-b]thiophene-4- ylidene]acetic acid, MW 284), which inhibits the release of interleukin-1 alpha and -beta from cultured murine macrophages or human mononuclear cells. The study included 12 patients (rheumatoid arthritis, n = 9; hemochromatotic arthropathy, n = 1; psoriatic arthropathy, n = 1; seronegative spondylarthropathy, n = 1). Eight patients were treated for a total of 8 weeks, receiving a median dose of 800 mg/d of the substance. Due to significant clinical benefits, two patients continued for a total of six months. Administration of the drug was discontinued in two patients because of severe urticaria and lack of compliance, respectively. Four out of 10 patients showed clinical improvement according to Ritchie-Index, pain score, ESR and CRP. Side effects were diffuse gastrointestinal symptoms (4/12), temporary impairment of liver function (4/12) and allergic skin reactions (3/12).
 ...
PMID:[Initial clinical experiences in the treatment of chronic polyarthritis with a new monokine release inhibitor]. 267 92


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>